ArticleJournal of gastrointestinal cancer2026
Integrative Machine-Learning Molecular Subtyping and Risk Scores of Circadian Rhythm-Related Prognostic Signatures in Colorectal Cancer.
Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeColorectal Cancer (CRC) exhibits considerable heterogeneity. Circadian Rhythm (CR) disruption is increasingly implicated in tumorigenesis and cancer progression.
methodsWe identified Circadian Rhythm-Related Genes (CRRGs) significantly associated with prognosis through differential expression analysis and univariate Cox regression from 1,184 samples, and established the molecular subtypes based on unsupervised clustering. Employing a combination of ten machine learning algorithms to 101 model configurations, we developed and validated a high-predictive-performance risk-scoring model (CRRGscore).
resultsCRC patients were stratified into two distinct molecular subtypes (Cluster A vs. B). Cluster B had worse prognosis, and tumor microenvironment of Cluster B was characterized by enhanced immune suppression and stromal activation. The RSF model demonstrated the best performance (C-index = 0.707) and was used to build the CRRGscore. This risk model showed outstanding predictive ability in the TCGA training set, with 1-, 3-, 5-year AUCs of 0.982, 0.978, 0.991, respectively. Its robustness was maintained across three independent validation sets. Patients in the High-risk group had significantly poorer overall survival (P < 0.001) and the risk score was significantly correlated with adverse clinical characteristics, like advanced tumor stage and recurrence/metastasis (P < 0.01). Further analysis revealed an immune-excluded/immunosuppressive subtype phenotype in the High-risk group. Drug sensitivity analysis indicated that the High-risk group was less sensitive to conventional chemotherapeutics and targeted agents, and identifying several potential alternative drugs.
conclusionThis model demonstrated robust predictive capability for patient survival outcomes, tumor microenvironment status, and chemotherapeutic response in the integrated cohorts, providing a crucial clinical tool for prognostic assessment in CRC.
Indexed as
Identifiers
41940921What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.